| 前收盘价格 | 1.94 |
| 收盘价格 | 1.99 |
| 成交量 | 16,398 |
| 平均成交量 (3个月) | 153,159 |
| 市值 | 50,754,400 |
| 价格/销量 (P/S) | 1.95 |
| 股市价格/股市净资产 (P/B) | 0.870 |
| 52周波幅 | |
| 利润日期 | 9 Aug 2024 - 13 Aug 2024 |
| 营业毛利率 | -85.75% |
| 营业利益率 (TTM) | -748.92% |
| 稀释每股收益 (EPS TTM) | -0.540 |
| 季度收入增长率 (YOY) | -69.70% |
| 流动比率 (MRQ) | 10.68 |
| 营业现金流 (OCF TTM) | -11.46 M |
| 杠杆自由现金流 (LFCF TTM) | -8.70 M |
| 资产报酬率 (ROA TTM) | -21.35% |
| 股东权益报酬率 (ROE TTM) | -36.01% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Ocuphire Pharma, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
0.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | 0.17 |
|
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 6.11% |
| 机构持股比例 | 8.70% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合